2024
Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006)
Sevinsky H, Rozakis R, Nepomuceno T, Malatesta J, Awsare B, Ashbrenner E, Kaplita S, Gentile K, Hussey E, Qureshi I, Coric V, Bertz R. Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects (S5.006). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205022.Peer-Reviewed Original ResearchSafety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects (P4-4.012)
Sevinsky H, Awsare B, Rozakis R, Gentile K, Mydlow P, Ashbrenner E, Ham R, Stock D, Qureshi I, Coric V, Bertz R. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects (P4-4.012). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205210.Peer-Reviewed Original ResearchHealthy subjects
2022
Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects (P2-2.001)
Bertz R, Anderson M, Collins J, Stringfellow J, Madonia J, Bharwaj R, Finley J, Stock D, Coric V, Croop R. Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects (P2-2.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.877.Peer-Reviewed Original ResearchP‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects
Bhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, Stock D, Coric V, Croop R, Bertz R. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Clinical Pharmacology In Drug Development 2022, 11: 889-897. PMID: 35304977, PMCID: PMC9311059, DOI: 10.1002/cpdd.1088.Peer-Reviewed Original ResearchConceptsBreast cancer resistance protein transporterPlasma concentration-time curveSingle oral doseGeometric mean ratiosConcentration-time curveP-glycoproteinOral doseHealthy subjectsSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistStrong P-glycoprotein inhibitorBreast cancer resistance protein (BCRP) inhibitionPeptide receptor antagonistTime 0Mean ratioP-glycoprotein inhibitorsP-glycoprotein transporterConcomitant administrationCrossover studyReceptor antagonistPreventive treatmentCyclosporineCoadministrationTransporter inhibitionPharmacokinetics
2020
Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117)
Hanna M, Coric V, Stringfellow J, Ivans A, Croop R. Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2117.Peer-Reviewed Original Research